Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fidia FDA Orphan Drug Designation for ONCOFID®-P for Malignant Mesothelioma
Details : ONCOFID®-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
Brand Name : Oncofid-P
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2021
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Divestment
Details : The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 23, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : Sanofi
Deal Size : Undisclosed
Deal Type : Divestment
LOOKING FOR A SUPPLIER?
Reset All
